Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents

References

• FreemanAJYoungstromEAMichalakESiegelRMeyersOIFindlingRLQuality of life in pediatric bipolar disorderPediatrics20091233e446e45219254981
   PubMed Web of Science ®Google Scholar
• OhJChangJGLeeSBSongDHCheonKAComparison of aripiprazole and other atypical antipsychotics for pediatric bipolar disorder: a retrospective chart review of efficacy and tolerabilityClin Psychopharmacol Neurosci2013112727924023551
   PubMed Web of Science ®Google Scholar
• SoutulloCAChangKDDíez-SuárezABipolar disorder in children and adolescents: international perspective on epidemiology and phenomenologyBipolar Disord20057649750616403175
   PubMed Web of Science ®Google Scholar
• StringarisASantoshPLeibenluftEGoodmanRYouth meeting symptom and impairment criteria for mania-like episodes lasting less than four days: an epidemiological enquiryJ Child Psychol Psychiatry2010511313819686330
   PubMed Web of Science ®Google Scholar
• BrunelleJConsoliATanguyMLPhenomenology, socio-demographic factors and outcome upon discharge of manic and mixed episodes in hospitalized adolescents: a chart reviewEur Child Adolesc Psychiatry200918318519319129964
   PubMed Web of Science ®Google Scholar
• ZuddasAZanniRUsalaTSecond generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studiesEur Neuropsychopharmacol201121860062021550212
   PubMed Web of Science ®Google Scholar
• YoungstromEVan MeterAAlgortaGPThe bipolar spectrum: myth or reality?Curr Psychiatry Rep201012647948920857347
   PubMed Web of Science ®Google Scholar
• Van MeterARMoreiraALYoungstromEAMeta-analysis of epidemiologic studies of pediatric bipolar disorderJ Clin Psychiatry20117291250125621672501
   PubMed Web of Science ®Google Scholar
• ChangKDThe use of atypical antipsychotics in pediatric bipolar disorderJ Clin Psychiatry200869Suppl 44818533762
   PubMedGoogle Scholar
• MorenoCLajeGBlancoCJiangHSchmidtABOlfsonMNational trends in the outpatient diagnosis and treatment of bipolar disorder in youthArch Gen Psychiatry20076491032103917768268
   PubMed Web of Science ®Google Scholar
• GoodwinGMMartinez-AranAGlahnDCVietaECognitive impairment in bipolar disorder: neurodevelopment or neurodegeneration? An ECNP expert meeting reportEur Neuropsychopharmacol2008181178779318725178
   PubMed Web of Science ®Google Scholar
• PerlisRHMiyaharaSMarangellLBLong-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD)Biol Psychiatry200455987588115110730
   PubMed Web of Science ®Google Scholar
• CarterTDMundoEParikhSVKennedyJLEarly age at onset as a risk factor for poor outcome of bipolar disorderJ Psychiatr Res200337429730312765852
   PubMed Web of Science ®Google Scholar
• LinPIMcInnisMGPotashJBClinical correlates and familial aggregation of age at onset in bipolar disorderAm J Psychiatry2006163224024616449477
   PubMed Web of Science ®Google Scholar
• LeverichGSPostRMKeckPEJrThe poor prognosis of childhood-onset bipolar disorderJ Pediatr2007150548549017452221
   PubMed Web of Science ®Google Scholar
• PostRMKowatchRAThe health care crisis of childhood-onset bipolar illness: some recommendations for its ameliorationJ Clin Psychiatry200667111512516426098
   PubMed Web of Science ®Google Scholar
• MankoskiRZhaoJCarsonWHMathewSJForbesRAYoung mania rating scale line item analysis in pediatric subjects with bipolar I disorder treated with aripiprazole in a short-term, double-blind, randomized studyJ Child Adolesc Psychopharmacol201121435936421823911
   PubMed Web of Science ®Google Scholar
• DoeyTAripiprazole in pediatric psychosis and bipolar disorder: a clinical reviewJ Affect Disord2012138SupplS15S2122406333
   PubMed Web of Science ®Google Scholar
• VietaEAtypical antipsychotics in the treatment of mood disordersCurr Opin Psychiatry20031612327
   Web of Science ®Google Scholar
• VietaEBourinMSanchezRAripoprazole Study GroupEffectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trialBr J Psychiatry200518723524216135860
   PubMed Web of Science ®Google Scholar
• TohenMGoldbergJFGonzalez-Pinto ArrillagaAMA 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute maniaArch Gen Psychiatry200360121218122614662554
   PubMed Web of Science ®Google Scholar
• BrecherMHuizarKQuetiapine monotherapy for acute mania associated with bipolar disorderInternational Conference on Bipolar Disorder (abstract)June 12–14, 2003Pittsburgh, PA
   Google Scholar
• McClellanJKowatchRFindlingRLWork Group on Quality IssuesPractice parameter for the assessment and treatment of children and adolescents with bipolar disorderJ Am Acad Child Adolesc Psychiatry200746110712517195735
   PubMed Web of Science ®Google Scholar
• KowatchRAFristadMBirmaherBTreatment guidelines for children and adolescents with bipolar disorderJ Am Acad Child Adolesc Psychiatry200544321323515725966
   PubMed Web of Science ®Google Scholar
• CorrellCUAssessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescentsJ Clin Psychiatry200869Suppl 4263618533766
   PubMed Web of Science ®Google Scholar
• HaasMDelbelloMPPandinaGRisperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled studyBipolar Disord200911768770019839994
   PubMed Web of Science ®Google Scholar
• DelbelloMPSchwiersMLRosenbergHLStrakowskiSMA double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent maniaJ Am Acad Child Adolesc Psychiatry200241101216122312364843
   PubMed Web of Science ®Google Scholar
• TohenMKryzhanovskayaLCarlsonGOlanzapine versus placebo in the treatment of adolescents with bipolar maniaAm J Psychiatry2007164101547155617898346
   PubMed Web of Science ®Google Scholar
• KeckPEJrMarcusRTourkodimitrisSA placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar maniaAm J Psychiatry200316091651165812944341
   PubMed Web of Science ®Google Scholar
• KikuchiTThe research and development of aripiprazole and its mechanism of actionJpn J Clin Psychopharmacol2007103464468
   Google Scholar
• KirinoEEfficacy and safety of aripiprazole in child and adolescent patientsEur Child Adolesc Psychiatry201221736136822447196
   PubMed Web of Science ®Google Scholar
• KirinoEAripiprazole in patients with autistic spectrum disorders: a review and case reportsAutism Open Access2012S1004
   Google Scholar
• KirinoEEfficacy and tolerability of pharmacotherapy options for the treatment of irritability in autistic childrenClin Med Insights Pediatr20148173024932108
   PubMedGoogle Scholar
• GreenawayMElbeDFocus on aripiprazole: a review of its use in child and adolescent psychiatryJ Can Acad Child Adolesc Psychiatry200918325026019718428
   PubMedGoogle Scholar
• BrownRTaylorMJGeddesJAripiprazole alone or in combination for acute maniaCochrane Database Syst Rev201312CD00500024346956
   PubMed Web of Science ®Google Scholar
• MarcusRNOwenRKamenLA placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorderJ Am Acad Child Adolesc Psychiatry200948111110111919797985
   PubMed Web of Science ®Google Scholar
• OwenRSikichLMarcusRNAripiprazole in the treatment of irritability in children and adolescents with autistic disorderPediatrics200912461533154019948625
   PubMed Web of Science ®Google Scholar
• SanfordMKeatingGMAripiprazole: in adolescents with schizophreniaPaediatr Drugs20079641942318052412
   PubMedGoogle Scholar
• BiedermanJMickESpencerTAn open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorderCNS Spectr200712968368917805214
   PubMed Web of Science ®Google Scholar
• FindlingRLNyilasMForbesRAAcute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled studyJ Clin Psychiatry200970101441145119906348
   PubMed Web of Science ®Google Scholar
• RobbASCarsonWHNyilasMChanges in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial dataJ Child Adolesc Psychopharmacol2010201333820166794
   PubMed Web of Science ®Google Scholar
• StahlSMDopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of actionJ Clin Psychiatry2001621292392411780870
   PubMed Web of Science ®Google Scholar
• TadoriYMiwaTTottoriKAripiprazole’s low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychoticEur J Pharmacol20055151–3101915894311
   PubMed Web of Science ®Google Scholar
• PotkinSGSahaARKujawaMJAripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorderArch Gen Psychiatry200360768169012860772
   PubMed Web of Science ®Google Scholar
• LahtiACWeilerMACoreyPKLahtiRACarlssonATammingaCAAntipsychotic properties of the partial dopamine agonist (−)-3-(3-hy droxyphenyl)-N-n-propylpiperidine(preclamol) in schizophreniaBiol Psychiatry19984312119442338
   PubMed Web of Science ®Google Scholar
• TammingaCACarlssonAPartial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosisCurr Drug Targets CNS Neurol Disord20021214114712769623
   PubMedGoogle Scholar
• TammingaCAPartial dopamine agonists in the treatment of psychosisJ Neural Transm2002109341142011956961
   PubMed Web of Science ®Google Scholar
• OlbrichRSchanzHAn evaluation of the partial dopamine agonist terguride regarding positive symptoms reduction in schizophrenicsJ Neural Transm Gen Sect19918432332361679338
   PubMed Web of Science ®Google Scholar
• OlbrichRSchanzHThe effect of the partial dopamine agonist terguride on negative symptoms in schizophrenicsPharmacopsychiatry19882163893902907647
   PubMed Web of Science ®Google Scholar
• ShapiroDARenockSArringtonEAripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacologyNeuropsychopharmacology20032881400141112784105
   PubMed Web of Science ®Google Scholar
• HeislerLKChuHMBrennanTJElevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant miceProc Natl Acad Sci U S A1998952515049150549844013
   PubMed Web of Science ®Google Scholar
• MeltzerHYLiZKanedaYIchikawaJSerotonin receptors: their key role in drugs to treat schizophreniaProg Neuropsychopharmacol Biol Psychiatry20032771159117214642974
   PubMed Web of Science ®Google Scholar
• DeBattistaCHawkinsJUtility of atypical antipsychotics in the treatment of resistant unipolar depressionCNS Drugs200923536937719453199
   PubMed Web of Science ®Google Scholar
• FernandezHHTrieschmannMEFriedmanJHAripiprazole for drug-induced psychosis in Parkinson disease: preliminary experienceClin Neuropharmacol20042714515090928
   PubMed Web of Science ®Google Scholar
• de QuervainDJHenkeKAerniAA functional genetic variation of the 5-HT2a receptor affects human memoryNat Neurosci20036111141114214566344
   PubMed Web of Science ®Google Scholar
• GrunderGKungelMEbrechtMGöröcsTModellSAripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophreniaPharmacopsychiatry200639Suppl 1S21S2516508892
   PubMed Web of Science ®Google Scholar
• HiroseTUwahodoYYamadaSMechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profileJ Psychopharmacol200418337538315358981
   PubMed Web of Science ®Google Scholar
• WirshingDABoydJAMengLRBallonJSMarderSRWirshingWCThe effects of novel antipsychotics on glucose and lipid levelsJ Clin Psychiatry2002631085686512416594
   PubMed Web of Science ®Google Scholar
• SargentPASharpleyALWilliamsCGoodallEMCowenPJ5-HT2C receptor activation decreases appetite and body weight in obese subjectsPsychopharmacology (Berl)199713333093129361339
   PubMed Web of Science ®Google Scholar
• NasrallahHAAtypical antipsychotic-induced metabolic side effects: insights from receptor-binding profilesMol Psychiatry2008131273517848919
   PubMed Web of Science ®Google Scholar
• KroezeWKHufeisenSJPopadakBAH1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugsNeuropsychopharmacology200328351952612629531
   PubMed Web of Science ®Google Scholar
• GoodnickPJJerryJMAripiprazole: profile on efficacy and safetyExpert Opin Pharmacother20023121773178112472374
   PubMedGoogle Scholar
• StahlSMShayeganDKThe psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practiceJ Clin Psychiatry200364Suppl 19612
   Google Scholar
• BoldenCCusackBRichelsonEAntagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cellsJ Pharmacol Exp Ther199226025765801346637
   PubMed Web of Science ®Google Scholar
• ShayeganDKStahlSMAtypical antipsychotics: matching receptor profile to individual patient’s clinical profileCNS Spectr2004910 Suppl 1161415475871
   PubMed Web of Science ®Google Scholar
• CorrellCUManuPOlshanskiyVNapolitanoBKaneJMMalhotraAKCardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescentsJAMA2009302161765177319861668
   PubMed Web of Science ®Google Scholar
• DaviesMAShefflerDJRothBLAripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacologyCNS Drug Rev200410431733615592581
   PubMedGoogle Scholar
• American Psychiatric AssociationPractice Guideline for the Treatment of Patients with Schizophrenia2nd edArlington, VAAmerican Psychiatric Association2004
   Google Scholar
• FindlingRLBlumerJLKauffmanRPharmacokinetic effects of aripiprazole in children and adolescents with conduct disorderPaper presented at: the XXIVth Collegium Internationale Neuro-Psychopharmacologicum Congress20–24 June, 2004Paris, France
   Google Scholar
• Abilify^® [prescribing information]Tokyo, JapanOtsuka Pharmaceutical Co2013 Available from: http://www.otsuka-us.com/Documents/Abilify.PI.pdfAccessed August 19, 2014
   Google Scholar
• CurranMPAripiprazole in the treatment of irritability associated with autistic disorder in paediatric patients: profile reportCNS Drugs201125980180221870890
   PubMed Web of Science ®Google Scholar
• CurranMPAripiprazole: in the treatment of irritability associated with autistic disorder in pediatric patientsPaediatr Drugs201113319720421500873
   PubMed Web of Science ®Google Scholar
• FindlingRLKauffmanRSalleeFRAn open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorderJ Child Adolesc Psychopharmacol200919443143919702495
   PubMed Web of Science ®Google Scholar
• FindlingRLCorrellCUNyilasMAripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled studyBipolar Disord201315213814923437959
   PubMed Web of Science ®Google Scholar
• MankoskiRStocktonGManosGAripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight changeJ Child Adolesc Psychopharmacol201323857257624138011
   PubMed Web of Science ®Google Scholar
• YoungstromEZhaoJMankoskiRClinical significance of treatment effects with aripiprazole versus placebo in a study of manic or mixed episodes associated with pediatric bipolar I disorderJ Child Adolesc Psychopharmacol2013232727923480324
   PubMed Web of Science ®Google Scholar
• TramontinaSZeniCPKetzerCRPheulaGFNarvaezJRohdeLAAripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trialJ Clin Psychiatry200970575676419389329
   PubMed Web of Science ®Google Scholar
• UttleyLKearnsBRenSStevensonMAripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar I disorder in children and adolescents: a NICE single technology appraisalPharmacoeconomics2013311198199024092620
   PubMed Web of Science ®Google Scholar
• GellerBLubyJLJoshiPA randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescentsArch Gen Psychiatry201269551552822213771
   PubMed Web of Science ®Google Scholar
• BarzmanDHDelBelloMPKowatchRAThe effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart reviewJ Child Adolesc Psychopharmacol200414459360015662152
   PubMed Web of Science ®Google Scholar
• BiedermanJMcDonnellMAWozniakJAripiprazole in the treatment of pediatric bipolar disorder: a systematic chart reviewCNS Spectr200510214114815685125
   PubMed Web of Science ®Google Scholar
• FraguasDCorrellCUMerchán-NaranjoJEfficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisonsEur Neuropsychopharmacol201121862164520702068
   PubMed Web of Science ®Google Scholar
• FleischhakerCHeiserPHennighausenKWeight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidoneJ Neural Transm2008115111599160818779922
   PubMed Web of Science ®Google Scholar
• Martínez-OrtegaJMDiaz-AtienzaFGutiérrez-RojasLJuradoDGurpeguiMConfounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescentsEur Child Adolesc Psychiatry20112011–1259759821927910
   PubMed Web of Science ®Google Scholar
• FindlingRLMankoskiRTimkoKA randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorderJ Clin Psychiatry2014751223024502859
   PubMed Web of Science ®Google Scholar
• FindlingRLRobbANyilasMA multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophreniaAm J Psychiatry2008165111432144118765484
   PubMed Web of Science ®Google Scholar
• SaferDJCalargeCASaferAMProlactin serum concentrations during aripiprazole treatment in youthJ Child Adolesc Psychopharmacol201323428228923647135
   PubMed Web of Science ®Google Scholar
• HoJGCaldwellRLMcDougleCJThe effects of aripiprazole on electrocardiography in children with pervasive developmental disordersJ Child Adolesc Psychopharmacol201222427728322849533
   PubMed Web of Science ®Google Scholar
• GermanòEItalianoDLambertiMECG parameters in children and adolescents treated with aripiprazole and risperidoneProg Neuropsychopharmacol Biol Psychiatry201451232724211841
   PubMed Web of Science ®Google Scholar